Clinical trials: Lenvatinib, open to volunteers
Hepatoblastoma, Pediatric Cancer
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
This study is a single-cohort study. Pediatric patients with advanced, relapsed/refractory hepatoblastoma who have previously failed first-line or higher systemic therapy will receive 2 cycles of treatment with sintilimab…
- Trial name
- NCT07188311
- Testing
- Pucotenlimab ,Lenvatinib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Sarcoma
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and…
- Trial name
- MAGNATE-S (NCT07359053)
- Testing
- Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib, Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai 6th People's Hospital
Advanced Thyroid Cancer Patients Who Received Target Therapy
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.
- Trial name
- NCT06195228
- Testing
- dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
- Where
- 8 sites in China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Thyroid Cancer, Thyroid Neoplasms
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as…
- Trial name
- NeoLATC (NCT07419932)
- Testing
- Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site
EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma
Those studies demonstrate strong rationale to combine a multikinase inhibitor targeting VEGFR, PDGFR with mTOR inhibitor. Moreover, another multi-targeted TKI, lenvatinib monotherapy showed promising activity in osteosarcoma.
- Trial name
- NCT07619950
- Testing
- Everolimus and Lenvatinib, Everolimus
- Volunteers
- 94 people
- Sponsor
- Yonsei University
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Effectiveness, Sexuality
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
- Trial name
- NCT05617859
- Testing
- Lenvatinib mesylate capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital